The Latest Breaking News from BioMarin

Cork’s pharmaceutical industry, vital to the local economy, is at risk as US trade policies threaten small towns reliant on the sector

BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?

The big names behind biotech stocks no longer want to merely treat diseases, they want to cure them. But it's going to be costly.

U.S. health regulators have approved a gene therapy for the most common form of hemophilia

PTC stock surged Wednesday after the company unveiled promising results for its rare disease treatment, a rival to BioMarin's Kuvan.

Dow Jones futures kick off the 2023 stock market after a "stay away" year. Q4 Tesla deliveries hit a record, but missed lowered views again.

The FDA just approved its most expensive drug ever — a hemophilia gene therapy from CSL and UniQure — and QURE stock popped Wednesday.

Neurocrine Biosciences leads five medical stocks near key support levels as the health care sector shows resilience in a sickly market.

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…